search
Back to results

Vitamin C, Vitamin B1 and Steroid in Sepsis

Primary Purpose

Sepsis, Severe

Status
Unknown status
Phase
Phase 4
Locations
Taiwan
Study Type
Interventional
Intervention
Ascorbic acid-Vitamin B1-Hydrocortisone
Placebo
Sponsored by
Far Eastern Memorial Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Sepsis, Severe

Eligibility Criteria

20 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • aged equal or over 20
  • admitted to MICU due to severe sepsis or septic shock

Exclusion Criteria:

  • Patients who are pregnant
  • known history of Vitamin C , Vitamin B or hydrocortisone (or other equivalent products) allergy

Sites / Locations

  • Far Eastern Memorial Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

ABC group (Ascorbic acid-Vitamin B1-Hydrocortisone) group

normal saline group

Arm Description

patients in study group, so called" ABC" (Ascorbic acid-Vitamin B1-Hydrocortisone) group, would receive intravenous Thiamine (200mg in 50 mL of 0.9% normal saline and was administered as a 30-min infusion every 12 hours for 4 days or until ICU discharge), Vitamin C (1.5g mixed in a 100-mL solution of normal saline and was administered as an infusion over 30 to 60 min every 6 hours for four days or until ICU discharge) as well as hydrocortisone 50mg every 6 hours (or other equivalent products) for 7 days

patients would receive 50mL 0.9% normal saline, 100 mL 0.9% normal saline with the same infusion rate and hydrocortisone dependent on the discretion of the attending physician

Outcomes

Primary Outcome Measures

The primary endpoint was the hospital survival.
hospital survival

Secondary Outcome Measures

duration of vasopressor therapy
duration of vasopressor therapy
requirement for renal replacement therapy in patients with acute kidney injury (AKI)
requirement for renal replacement therapy in patients with acute kidney injury (AKI)
ICU length of stay (LOS)
ICU length of stay (days)
change of Acute Physiology And Chronic Health Evaluation II (APACH II) score over the first 72 hours
APACH II score (total 0~100) is a score to evaluate the mortality rate of ICU patients, higher values represent a worse outcome. It includes: (A) PaO2 (depending on FiO2) Temperature (rectal) Mean arterial pressure pH arterial Heart rate Respiratory rate Sodium (serum) Potassium (serum) Creatinine Hematocrit White blood cell count (B) age points (score: 0~6) (C) chronic health problems (liver cirrhosis, dialysis, COPD, congestive heart failure, immunocompromised)
change of Acute Physiology And Chronic Health Evaluation II (APACH II) score over the first 72 hours
PaO2 (depending on FiO2): mmHg
change of Acute Physiology And Chronic Health Evaluation II (APACH II) score over the first 72 hours
Temperature ( Celsius degrees)
change of Acute Physiology And Chronic Health Evaluation II (APACH II) score over the first 72 hours
Mean arterial pressure : mmHg
change of Acute Physiology And Chronic Health Evaluation II (APACH II) score over the first 72 hours
pH arterial
change of Acute Physiology And Chronic Health Evaluation II (APACH II) score over the first 72 hours
Heart rate: bpm
change of Acute Physiology And Chronic Health Evaluation II (APACH II) score over the first 72 hours
Respiratory rate: 1/min
change of Acute Physiology And Chronic Health Evaluation II (APACH II) score over the first 72 hours
Sodium (serum): mmol/L
change of Acute Physiology And Chronic Health Evaluation II (APACH II) score over the first 72 hours
Potassium (serum): mmol/L
change of Acute Physiology And Chronic Health Evaluation II (APACH II) score over the first 72 hours
Creatinine: mg/dL
change of Acute Physiology And Chronic Health Evaluation II (APACH II) score over the first 72 hours
Hematocrit: %
change of Acute Physiology And Chronic Health Evaluation II (APACH II) score over the first 72 hours
White blood cell count: 10 3/μL
change of Acute Physiology And Chronic Health Evaluation II (APACH II) score over the first 72 hours
age: years
change of Acute Physiology And Chronic Health Evaluation II (APACH II) score over the first 72 hours
chronic health problems (liver cirrhosis, dialysis, COPD, congestive heart failure, immunocompromised): None: 0 point Non-surgical: 5 points Emergent operation: 5 points
Sequential Organ Failure Assessment score (SOFA score) over the first 72 hours
PaO₂: mm Hg
Sequential Organ Failure Assessment score (SOFA score) over the first 72 hours
Platelets: ×10³/µL
Sequential Organ Failure Assessment score (SOFA score) over the first 72 hours
Glasgow Coma Scale: points 15: 0 13-14: +1 10-12: +2 6-9: +3 <6: +4
Sequential Organ Failure Assessment score (SOFA score) over the first 72 hours
Bilirubin: mg/dL
Sequential Organ Failure Assessment score (SOFA score) over the first 72 hours
Mean arterial pressure: mmHg
Sequential Organ Failure Assessment score (SOFA score) over the first 72 hours
Creatinine: mg/dL

Full Information

First Posted
December 11, 2018
Last Updated
December 4, 2019
Sponsor
Far Eastern Memorial Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT04039815
Brief Title
Vitamin C, Vitamin B1 and Steroid in Sepsis
Official Title
Effects of Vitamin C, Thiamine and Hydrocortisone in Septic Shock: a Randomized, Controlled Trial
Study Type
Interventional

2. Study Status

Record Verification Date
December 2018
Overall Recruitment Status
Unknown status
Study Start Date
December 3, 2019 (Actual)
Primary Completion Date
December 31, 2020 (Anticipated)
Study Completion Date
December 31, 2020 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Far Eastern Memorial Hospital

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
A randomized controlled trial to test the synergic modulation effect of vitamin C, thiamine and hydrocortisone in patients with severe sepsis or septic shock.
Detailed Description
Management of sepsis bases on three components: infection control, haemodynamic stabilization and modulation of the septic response. Many clinical trials conducted agents to block the inflammatory cascade, such as corticosteroids, anti-endotoxins antibodies, tumor necrosis factor (TNF) antagonists, interleukin-1-receptor antagonists, and so on, but none has proven effective to date. A safe, effective, ready available therapy is desperately required. Thiamine is a key co-factor for pyruvate dehydrogenase, alpha-ketoglutarate dehydrogenase, and transketolase. All the three enzymes are required to complete Krebs Cycle to prevent from lactate production. Previous studies have found thiamine deficiency to be prevalent in septic shock and other critically ill conditions. One pilot study also proved patients with septic shock and baseline thiamine deficiency would have significant lower lactate level at 24 hours after administration of thiamine. HYPRESS (hydrocortisone for Prevention of Septic Shock) study failed to demonstrate an outcome benefit from a hydrocortisone infusion in patients with sepsis. Vitamin C is a potent antioxidant that directly scavenges oxygen free radicals, can restores other cellular antioxidants and plays a role in preserving endothelial function and microcirculatory flow as well. Though previous studies suggested that hydrocortisone and vitamin C alone have little impact on the clinical outcome of patients with sepsis. Vitamin C and hydrocortisone have many overlapping and synergic pathophysiologic effects in sepsis. Both drugs are required for the synthesis of catechlamines and increase vasopressor sensitivity. Both drugs can down-regulating the production of proinflammatory mediators, increase tight junctions between endothelial and epithelial cells, preserve endothelial function and microcirculatory flow. Marik et al published their study in CHEST (June 2017) resulting the benefits of combination of Vitamin B1, Vitamin C and hydrocortisone to severe sepsis and septic shock. However, small sample size and some bias due to imbalanced baseline and study method could confound the results. Herein, we would like to lead a randomized controlled trial to test the synergic modulation effect of vitamin C, thiamine and hydrocortisone in patients with severe sepsis or septic shock.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Sepsis, Severe

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Model Description
double blind, randomized-controlled trial
Masking
ParticipantCare ProviderOutcomes Assessor
Masking Description
as above
Allocation
Randomized
Enrollment
80 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
ABC group (Ascorbic acid-Vitamin B1-Hydrocortisone) group
Arm Type
Experimental
Arm Description
patients in study group, so called" ABC" (Ascorbic acid-Vitamin B1-Hydrocortisone) group, would receive intravenous Thiamine (200mg in 50 mL of 0.9% normal saline and was administered as a 30-min infusion every 12 hours for 4 days or until ICU discharge), Vitamin C (1.5g mixed in a 100-mL solution of normal saline and was administered as an infusion over 30 to 60 min every 6 hours for four days or until ICU discharge) as well as hydrocortisone 50mg every 6 hours (or other equivalent products) for 7 days
Arm Title
normal saline group
Arm Type
Placebo Comparator
Arm Description
patients would receive 50mL 0.9% normal saline, 100 mL 0.9% normal saline with the same infusion rate and hydrocortisone dependent on the discretion of the attending physician
Intervention Type
Drug
Intervention Name(s)
Ascorbic acid-Vitamin B1-Hydrocortisone
Intervention Description
intravenous Thiamine (200mg in 50 mL of 0.9% normal saline and was administered as a 30-min infusion every 12 hours for 4 days or until ICU discharge), plus Vitamin C (1.5g mixed in a 100-mL solution of normal saline and was administered as an infusion over 30 to 60 min every 6 hours for four days or until ICU discharge) as well as hydrocortisone 50mg every 6 hours (or other equivalent products) for 7 days
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
patients would receive 50mL 0.9% normal saline, 100 mL 0.9% normal saline with the same infusion rate and hydrocortisone dependent on the discretion of the attending physician
Primary Outcome Measure Information:
Title
The primary endpoint was the hospital survival.
Description
hospital survival
Time Frame
30 days
Secondary Outcome Measure Information:
Title
duration of vasopressor therapy
Description
duration of vasopressor therapy
Time Frame
72 hours
Title
requirement for renal replacement therapy in patients with acute kidney injury (AKI)
Description
requirement for renal replacement therapy in patients with acute kidney injury (AKI)
Time Frame
72 hours
Title
ICU length of stay (LOS)
Description
ICU length of stay (days)
Time Frame
4 days
Title
change of Acute Physiology And Chronic Health Evaluation II (APACH II) score over the first 72 hours
Description
APACH II score (total 0~100) is a score to evaluate the mortality rate of ICU patients, higher values represent a worse outcome. It includes: (A) PaO2 (depending on FiO2) Temperature (rectal) Mean arterial pressure pH arterial Heart rate Respiratory rate Sodium (serum) Potassium (serum) Creatinine Hematocrit White blood cell count (B) age points (score: 0~6) (C) chronic health problems (liver cirrhosis, dialysis, COPD, congestive heart failure, immunocompromised)
Time Frame
72 hours
Title
change of Acute Physiology And Chronic Health Evaluation II (APACH II) score over the first 72 hours
Description
PaO2 (depending on FiO2): mmHg
Time Frame
72 hours
Title
change of Acute Physiology And Chronic Health Evaluation II (APACH II) score over the first 72 hours
Description
Temperature ( Celsius degrees)
Time Frame
72 hours
Title
change of Acute Physiology And Chronic Health Evaluation II (APACH II) score over the first 72 hours
Description
Mean arterial pressure : mmHg
Time Frame
72 hours
Title
change of Acute Physiology And Chronic Health Evaluation II (APACH II) score over the first 72 hours
Description
pH arterial
Time Frame
72 hours
Title
change of Acute Physiology And Chronic Health Evaluation II (APACH II) score over the first 72 hours
Description
Heart rate: bpm
Time Frame
72 hours
Title
change of Acute Physiology And Chronic Health Evaluation II (APACH II) score over the first 72 hours
Description
Respiratory rate: 1/min
Time Frame
72 hours
Title
change of Acute Physiology And Chronic Health Evaluation II (APACH II) score over the first 72 hours
Description
Sodium (serum): mmol/L
Time Frame
72 hours
Title
change of Acute Physiology And Chronic Health Evaluation II (APACH II) score over the first 72 hours
Description
Potassium (serum): mmol/L
Time Frame
72 hours
Title
change of Acute Physiology And Chronic Health Evaluation II (APACH II) score over the first 72 hours
Description
Creatinine: mg/dL
Time Frame
72 hours
Title
change of Acute Physiology And Chronic Health Evaluation II (APACH II) score over the first 72 hours
Description
Hematocrit: %
Time Frame
72 hours
Title
change of Acute Physiology And Chronic Health Evaluation II (APACH II) score over the first 72 hours
Description
White blood cell count: 10 3/μL
Time Frame
72 hours
Title
change of Acute Physiology And Chronic Health Evaluation II (APACH II) score over the first 72 hours
Description
age: years
Time Frame
72 hours
Title
change of Acute Physiology And Chronic Health Evaluation II (APACH II) score over the first 72 hours
Description
chronic health problems (liver cirrhosis, dialysis, COPD, congestive heart failure, immunocompromised): None: 0 point Non-surgical: 5 points Emergent operation: 5 points
Time Frame
72 hours
Title
Sequential Organ Failure Assessment score (SOFA score) over the first 72 hours
Description
PaO₂: mm Hg
Time Frame
72 hours
Title
Sequential Organ Failure Assessment score (SOFA score) over the first 72 hours
Description
Platelets: ×10³/µL
Time Frame
72 hours
Title
Sequential Organ Failure Assessment score (SOFA score) over the first 72 hours
Description
Glasgow Coma Scale: points 15: 0 13-14: +1 10-12: +2 6-9: +3 <6: +4
Time Frame
72 hours
Title
Sequential Organ Failure Assessment score (SOFA score) over the first 72 hours
Description
Bilirubin: mg/dL
Time Frame
72 hours
Title
Sequential Organ Failure Assessment score (SOFA score) over the first 72 hours
Description
Mean arterial pressure: mmHg
Time Frame
72 hours
Title
Sequential Organ Failure Assessment score (SOFA score) over the first 72 hours
Description
Creatinine: mg/dL
Time Frame
72 hours

10. Eligibility

Sex
All
Minimum Age & Unit of Time
20 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: aged equal or over 20 admitted to MICU due to severe sepsis or septic shock Exclusion Criteria: Patients who are pregnant known history of Vitamin C , Vitamin B or hydrocortisone (or other equivalent products) allergy
Facility Information:
Facility Name
Far Eastern Memorial Hospital
City
Taipei County
ZIP/Postal Code
100
Country
Taiwan

12. IPD Sharing Statement

Plan to Share IPD
No
IPD Sharing Plan Description
IPD are not to be shared with other researchers

Learn more about this trial

Vitamin C, Vitamin B1 and Steroid in Sepsis

We'll reach out to this number within 24 hrs